ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...
Aug. 26 (UPI) --The Food and Drug Administration on Monday approved Insulet's Omnipod 5 automated insulin delivery system for people with Type 2 diabetes. In 2022, the FDA signed off on the system for ...
Q2 revenue rises 32.9% Y/Y to $649.1 million, beating estimates and topping guidance range. Insulet raises FY25 sales outlook to $2.57 billion–$2.63 billion, above prior view of $2.47 billion–$2.53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback